Aurinia Pharmaceuticals Inc logo

AUP - Aurinia Pharmaceuticals Inc Share Price

C$19.22 -0.4  -1.9%

Last Trade - 10/08/20

Sector
Healthcare
Size
Mid Cap
Market Cap £1.41bn
Enterprise Value £1.20bn
Revenue £244k
Position in Universe 160th / 2675
Bullish
Bearish
Unlock AUP Revenue
Momentum
Relative Strength (%)
1m -13.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -31.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.28 0.24 0.17 0.42 0.46 0.32 0.20 95.0 +2.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Aurinia Pharmaceuticals Inc revenues remained flat at $30K. Net loss increased 33% to $16.5M. Revenues reflect market conditions. Higher net loss reflects Selling/General/Admin Expense increase from $3.9M to $11.1M (expense), Research and development increase of 30% to $13.8M (expense), Foreign exchange loss (gain) and other increase from $62K to $1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AUP Revenue Unlock AUP Revenue

Net Income

AUP Net Income Unlock AUP Revenue

Normalised EPS

AUP Normalised EPS Unlock AUP Revenue

PE Ratio Range

AUP PE Ratio Range Unlock AUP Revenue

Dividend Yield Range

AUP Dividend Yield Range Unlock AUP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AUP EPS Forecasts Unlock AUP Revenue
Profile Summary

Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. It is developing voclosporin in multiple indications. Voclosporin is an investigational therapy. It is developing voclosporin for the treatment of lupus nephritis (LN) and other proteinuric diseases. It is also advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Voclosporin is a calcineurin inhibitor (CNI). By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated April 27, 2009
Public Since September 19, 2000
No. of Shareholders: n/a
No. of Employees: 62
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P/TSX Composite , S&P - Tse 300 Capped ,
Exchange Toronto Stock Exchange
Shares in Issue 126,038,228
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AUP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AUP
Upcoming Events for AUP
Monday 10th August, 2020
Aurinia Pharmaceuticals Inc at BTIG Virtual Biotechnology Conference
Tuesday 11th August, 2020
Q2 2020 Aurinia Pharmaceuticals Inc Earnings Call
Thursday 12th November, 2020 Estimate
Q3 2020 Aurinia Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Aurinia Pharmaceuticals Inc
What is the Aurinia Pharmaceuticals Inc share price?

As of 10/08/20, shares in Aurinia Pharmaceuticals Inc are trading at C$19.22, giving the company a market capitalisation of £1.41bn. This share price information is delayed by 15 minutes.

How has the Aurinia Pharmaceuticals Inc share price performed this year?

Shares in Aurinia Pharmaceuticals Inc are currently trading at C$19.22 and the price has moved by 0.159k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aurinia Pharmaceuticals Inc price has moved by 0.155k% over the past year.

What are the analyst and broker recommendations for Aurinia Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Aurinia Pharmaceuticals Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aurinia Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Aurinia Pharmaceuticals Inc next release its financial results?

Aurinia Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Aurinia Pharmaceuticals Inc dividend yield?

Aurinia Pharmaceuticals Inc does not currently pay a dividend.

Does Aurinia Pharmaceuticals Inc pay a dividend?

Aurinia Pharmaceuticals Inc does not currently pay a dividend.

When does Aurinia Pharmaceuticals Inc next pay dividends?

Aurinia Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Aurinia Pharmaceuticals Inc shares?

To buy shares in Aurinia Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aurinia Pharmaceuticals Inc?

Shares in Aurinia Pharmaceuticals Inc are currently trading at C$19.22, giving the company a market capitalisation of £1.41bn.

Where are Aurinia Pharmaceuticals Inc shares listed? Where are Aurinia Pharmaceuticals Inc shares listed?

Here are the trading details for Aurinia Pharmaceuticals Inc:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: AUP
What kind of share is Aurinia Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Aurinia Pharmaceuticals Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aurinia Pharmaceuticals Inc share price forecast 2020?

Shares in Aurinia Pharmaceuticals Inc are currently priced at C$19.22. At that level they are trading at 31.68% premium to the analyst consensus target price of 0.00.

Analysts covering Aurinia Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.9 for the next financial year.

How can I tell whether the Aurinia Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aurinia Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -18.02%. At the current price of C$19.22, shares in Aurinia Pharmaceuticals Inc are trading at -3.51% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aurinia Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Aurinia Pharmaceuticals Inc.

Who are the key directors of Aurinia Pharmaceuticals Inc?

Aurinia Pharmaceuticals Inc's management team is headed by:

Dennis Bourgeault - CFO
Robert Huizinga - EVP
Michael Martin - COO
Benjamin Rovinski - IND
Neil Solomons - CMO
Lawrence Mandt - VPR
Celia Economides - VPR
Lorin Randall - LED
George Milne - CHM
Joseph Hagan - IND
Michael Hayden - IND
Peter Greenleaf - PRE
Daniel Billen - DRC
David Jayne - IND
Erik Eglite - SVP
Glenn Schulman - SVP
Chris Hays - VPR
Fran Lynch - VPR
Cara Felish - VPR
R. Hector MacKay-Dunn - DRC
Maxwell Donley - EVP
Who are the major shareholders of Aurinia Pharmaceuticals Inc?

Here are the top five shareholders of Aurinia Pharmaceuticals Inc based on the size of their shareholding:

HealthCor Management, L.P. Hedge Fund
Percentage owned: 7.75% (9.76m shares)
ILJIN SNT Co., Ltd. Corporation
Percentage owned: 6.65% (8.38m shares)
Consonance Capital Management LP Hedge Fund
Percentage owned: 5.48% (6.91m shares)
New Enterprise Associates (NEA) Venture Capital
Percentage owned: 4.1% (5.17m shares)
Point72 Asset Management, L.P. Hedge Fund
Percentage owned: 3.7% (4.67m shares)
Similar to AUP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.